Coherus Biosciences (NASDAQ:CHRS) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Monday.
Several other research analysts also recently commented on CHRS. Zacks Investment Research downgraded Coherus Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, December 4th. BidaskClub upgraded Coherus Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, January 31st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Coherus Biosciences currently has an average rating of “Buy” and an average target price of $27.20.
CHRS opened at $14.58 on Monday. Coherus Biosciences has a 52 week low of $8.32 and a 52 week high of $20.66. The company has a debt-to-equity ratio of 8.29, a quick ratio of 5.31 and a current ratio of 5.31.
Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.08). Sell-side analysts expect that Coherus Biosciences will post -3.12 earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC bought a new stake in Coherus Biosciences during the 2nd quarter valued at $118,000. Roman Butler Fullerton & Co. bought a new stake in Coherus Biosciences during the 4th quarter valued at $122,000. State Board of Administration of Florida Retirement System boosted its position in Coherus Biosciences by 16.5% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 22,095 shares of the biotechnology company’s stock valued at $200,000 after acquiring an additional 3,122 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Coherus Biosciences during the 3rd quarter valued at $282,000. Finally, Boston Advisors LLC boosted its position in Coherus Biosciences by 12.7% during the 4th quarter. Boston Advisors LLC now owns 33,060 shares of the biotechnology company’s stock valued at $299,000 after acquiring an additional 3,725 shares in the last quarter. 93.39% of the stock is currently owned by institutional investors and hedge funds.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.
Read More: Market Capitalization in the Stock Market
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.